Genentech To Acquire AC Immune’s Beta-Amyloid Antibodies For Alzheimer’s Research
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech will pay more than $300 million for preclinical conformation-specific antibodies against beta-amyloid.
You may also be interested in...
AC Immune Seeks Partner For First Anti-Tau Vaccine To Reach The Clinic
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
Deals of the Week: Sanofi/Joslin; Merck/Ambrx; Genentech/AC Immune; GSK/Liquidia; Roche/Seaside
Walgreens’ deal to acquire Alliance Boots vastly expands its international presence but got a chilly reception on Wall Street.
NTB Measure Gains Ground In Alzheimer's
Investigator in Elan, Lilly and Myriad trials tells “The Pink Sheet” DAILY he is generally optimistic.